Apriori Bio
$1.1M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Apriori Bio is currently valued at N/A as of July 8, 2024. The company has raised a total of $51.1M in funding.
Investment Perspective
Apriori Bio's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Apriori Bio Worth in 2025?
As of 2025, Apriori Bio is valued at N/A, based on the company's Early Stage VC funding round in July 8, 2024. This valuation positions Apriori Bio as one of the leading private companies in the sector.
Apriori Bio Valuation History
Apriori Bio's funding history demonstrates steady growth and investor confidence.
How Apriori Bio Valuation is Determined
Private company valuations like Apriori Bio's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Apriori Bio Valuation FAQs
Is Apriori Bio profitable?
Apriori Bio has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Apriori Bio's valuation compare to competitors?
Apriori Bio is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Apriori Bio IPO?
Apriori Bio has not announced plans for an initial public offering. Until an IPO, investors can access Apriori Bio shares through secondary market platforms.